New Two-Punch strategy aims to control aggressive prostate cancer
NCT ID NCT05189457
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests a sequential treatment approach for men with high-risk metastatic prostate cancer that is still sensitive to hormone therapy. In the first step, patients receive hormone therapy (LHRH analog plus a newer hormonal drug like abiraterone or enzalutamide). In the second step, they receive chemotherapy (docetaxel) along with continued hormone therapy. The goal is to see if this two-punch strategy improves overall survival. The study enrolled 32 participants and is no longer recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Luteinizing hormone releasing hormone (LHRH) analog, new hormonal agent (abiraterone or enzalutamide), and docetaxel chemotherapy
- What this could lead to
- If successful, this sequential approach could improve survival and disease control for men with high-risk metastatic prostate cancer.
- What could go wrong
- This is a small, early-phase trial with only 32 participants. The results may not apply to all patients, and the combination therapy carries risks like infection, fatigue, and hormone-related side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new tracer light up hidden prostate cancer?
- Could deep breaths before surgery ward off Post-Op confusion?
- A second look: MRI screening may spot hidden prostate cancers
- Can precision protons spare the bowel in prostate cancer?
- AI coaches doctors on cancer risk talks
- Can an immune booster make hormone therapy work better against prostate cancer?